Compare IMCR & VSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCR | VSAT |
|---|---|---|
| Founded | 2008 | 1986 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 9.6B |
| IPO Year | 2016 | 1996 |
| Metric | IMCR | VSAT |
|---|---|---|
| Price | $36.16 | $76.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $66.33 | $59.80 |
| AVG Volume (30 Days) | 413.9K | ★ 2.0M |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 30.39 | ★ 94.42 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $249,428,000.00 | N/A |
| Revenue This Year | $14.57 | $5.32 |
| Revenue Next Year | $8.21 | $3.57 |
| P/E Ratio | $152.39 | ★ N/A |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $27.56 | $25.50 |
| 52 Week High | $40.71 | $93.03 |
| Indicator | IMCR | VSAT |
|---|---|---|
| Relative Strength Index (RSI) | 64.48 | 49.91 |
| Support Level | $35.46 | $67.49 |
| Resistance Level | $37.25 | $90.40 |
| Average True Range (ATR) | 1.32 | 5.60 |
| MACD | 0.05 | -0.29 |
| Stochastic Oscillator | 87.76 | 38.01 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Viasat Inc an world-wide provider of communications technologies and services, focused on making connectivity accessible, available and secure for current and future customers world-wide. The company has two reportable segments: communication services and defense and advanced technologies. It generates majority of revenue from communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers. It has presence in United States and Outside United States. The company generates majority of revenue from United States. Its products are Antennas, Terminals & radios, Modems, Semiconductors, Cybersecurity, Software & services, Home internet.